Month: March 2022

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that, on February 28, 2022 the Compensation Committee of X4’s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 22,250 shares of X4’s common stock and restricted stock units covering 3,500 shares of X4’s common stock. These stock awards were granted as an inducement material...

BURLINGTON, Mass. and JERUSALEM, March 01, 2022 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present and participate in one-on-one investor meetings at the 32nd Annual Oppenheimer Healthcare Conference. Event: 32nd Annual Oppenheimer Healthcare ConferenceConference Date: Tuesday, March 15 – Thursday, February 17, 2022Presentation: Wednesday, March 16, 2022, at 2:40pm ET Management will also meet with investors during the event. Investors interested in meeting with the BrainsWay management team during the conference should contact their Oppenheimer & Co. representative. About BrainsWayBrainsWay...

MENLO PARK, Calif., March 01, 2022 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (“TLIS”), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report fourth quarter and full year 2021 financial and operational results on Tuesday, March 15, 2022, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Interested parties may access the live call via telephone by dialing 833-715-1329 for participants in the U.S. or Canada and 430-775-1933 for international callers, using conference ID 3692993. A live and archived webcast of the event can be accessed via the News & Events page of...

ER-Kim Gains Exclusive Rights to Commercialize QRX003 to Six Additional Countries 60 Countries Now Covered by Partnership Agreements for QRX003ASHBURN, Va., March 01, 2022 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has extended its exclusive Distribution Agreement with ER-Kim, a partner for biotech companies in Central and Eastern Europe (“CCE”), for QRX003, the Company’s investigational treatment for Netherton Syndrome, a rare and devastating genetic disease for which there is currently no available treatment or cure. Under the terms of the revenue sharing agreement, which was initially announced earlier in February 2022, ER-Kim...

YAVNE, Israel, March 01, 2022 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming investor conferences in March. Details for each is a follows:Cowen’s 42nd Annual Health Care ConferenceDate: Wednesday, March 9, 2022Time: 9:10 am ETLink: Click here   OppenheimerDate: March 17, 2022Time: 11:20 am ETLink: Click hereA replay of the fireside chat and presentation will be available on the Events page of the MediWound Investor Relations website at https://ir.mediwound.com/events-and-presentations. About MediWound Ltd.MediWound is a biopharmaceutical company that develops, manufactures, and commercializes novel, cost...

SAN FRANCISCO, March 01, 2022 (GLOBE NEWSWIRE) — Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today announced the company will be presenting in the upcoming JMP Securities Technology Conference in San Francisco. Manny Krakaris, Chief Executive Officer of Augmedix, will be presenting on Tuesday, March 8, 2022, at 11:30 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investor Relations” section of the company’s website at: https://ir.augmedix.com/news-events/ir-calendar. About Augmedix Augmedix, Inc. (Nasdaq: AUGX) provides automated medical documentation and data services to large healthcare systems and physician practices, supporting medical offices, clinics, hospitals, emergency departments, and telemedicine nationwide....

On schedule to run a full pilot on Li and other high-value battery minerals in 2022Lithium Hydroxide Lithium Hydroxide produced at the Aqua Metals Innovation Center in Tahoe Reno Industrial Center, NV.Lithium Hydroxide and Black Mass The Lithium hydroxide was produced from black mass made up of a mix of lithium-ion batteries. Li AquaRefining will be able to process black mass made from any mix of lithium-ion batteries.RENO, Nev., March 01, 2022 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS) (“Aqua Metals” or the “Company”), a leading innovator in metals recycling with its AquaRefining™ technology, has achieved a key milestone and potentially an important industry breakthrough by producing its first lithium hydroxide from lithium-ion battery black mass at the Company’s Innovation Center in the...

SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will provide a corporate update and participate in one-on-one investor meetings at the Cowen 42nd Annual Health Care Conference taking place virtually on Monday, March 7, 2022, at 11:10 a.m. ET. The presentation will be available through the Cowen conference portal and will also be available through the Investors & Media section of UNITY’s website. An archived replay will be available for 90 days following the event. About UNITY UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines...

IRVINE, Calif., March 01, 2022 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the appointment of Mr. Robert Warner to its board of directors. Mr. Warner will serve as a member of the Audit Committee of the board. “We are pleased to welcome Robert as a new independent director to our board. Mr. Warner’s decades of executive operating experience, including internationally, will be highly valuable to Inari as we enter the next phase of our mission to treat and transform the lives of patients suffering from venous and other diseases,” said Bill Hoffman, Inari’s Chief Executive Officer. From August 2015 to February 2018, Mr. Warner served as President and General Manager of Alcon...

Evolution Credit Limited up to SEK 260,000,000 and up to NOK 135,000,000 Senior Unsecured Callable Bonds 2013/2028 ISIN: SE 000 5392560 and NO 001 0689342 (the “Bonds”) Johannesburg, 1 March 2022 Reference is made to the terms and conditions for the Bonds, originally dated 16 September 2013, as amended and restated, most recently by an amendment and restatement agreement dated 22 September 2020 (the “Terms and Conditions“). Partial repayment In addition to scheduled amortizations, the Company is obliged to apply excess cash to repay Senior Unsecured Loans. If repayments are made under Senior Unsecured Loans, corresponding pro rata payments shall be made under the Bonds. The Company will therefore make an increased early partial redemption of the Bonds pursuant to Clauses 9.6 (Mandatory redemption pro rata in case...